Freenome, Inc. — Form 8-K/A
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K/A
▲ Likely positive
significance 72/100
What the filing says
On July 20, 2026, Freenome Holdings completed a reverse merger with PCSC (renamed Freenome, Inc.), receiving $295.5M net proceeds ($310.7M gross including $240M PIPE). The FDA approved SimpleScreen CRC in July 2026, triggering a $100M milestone payment from Abbott (formerly Exact Sciences). As of June 30, 2026 (pre-merger), Freenome held $102M cash; H1 2026 net loss was $132.6M on $6.5M revenue; accumulated deficit reached $1.5B. The Roche convertible note ($75M principal + $2.5M interest) converted to 6.46M shares at closing.
Why this rating
Material capital infusion ($295.5M) and first FDA approval substantially strengthen liquidity runway (est. through 2028). Relative to $91.6M market cap pre-filing, transformational for near-term operations but company remains pre-commercial with massive accumulated losses.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.